ReviewCold Spring Harbor perspectives in medicine2012
The VEGF pathway in cancer and disease: responses, resistance, and the path forward.
Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed.
- Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors.Cancer chemotherapy and pharmacology · 2014Trial
- Voltage-tunable plasma-activated water: a strategy for combating peri-implantitis via dual-path biofilm disruption and vascular regeneration.Clinical oral investigations · 2026Article
- Oxidative Stress Mediated by Macrophages Promotes Angiogenesis and Early Development of Endometriosis.Antioxidants (Basel, Switzerland) · 2026Article
- A novel anti-PD-L1/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model.Journal of translational medicine · 2025Article
- Recombinant oncolytic virus NDV-anti-VEGFR2 enhances radiotherapy sensitivity in NSCLC by targeting VEGF signaling and impairing DNA repair.Gene therapy · 2025Article
- Chemoresistance Evolution in Ovarian Cancer Delineated by Single-Cell RNA Sequencing.International journal of molecular sciences · 2025Article
- Adipocytokine Protein Expression from Visceral Fat Differs Significantly Based on Diet, Sex, and Age in C3H/HeJ Mice Fed Long-Term, High-Fat Diets, ± Ammonium-Hydroxide-Supplemented Dietary Protein.Current issues in molecular biology · 2025Article
- Inhibitory effects of carbohydrazide indole derivative on micro-blood vessel growth using ex vivo, in vivo, and in vitro assays.In vitro cellular & developmental biology. Animal · 2025Article
- Anti-angiogenic and anti-oxidant effects of 2-NTI indole derivative vs. suramin in ex vivo, in vivo, and in vitro studies.Cytotechnology · 2025Article
- Editorial: Advances in the research of diabetic retinopathy, volume III.Frontiers in endocrinology · 2025Article
- Engineering growth factor ligands and receptors for therapeutic innovation.Trends in cancer · 2024Review
- Pairwise analysis of gene expression for oral squamous cell carcinoma via a large-scale transcriptome integration.Journal of cellular and molecular medicine · 2024Article
- Immune Cell Migration to Cancer.Cells · 2024Review
- Carbon nanotubes targeted to the tumor microenvironment inhibit metastasis in a preclinical model of melanoma.Bioactive materials · 2024Article
- Decoding oral cancer: insights from miRNA expression profiles and their regulatory targets.Frontiers in molecular biosciences · 2024Article
- CXCL10 promotes melanoma angiogenesis and tumor growth.Animal cells and systems · 2024Article
- Gene Immunotherapy of Colon Carcinoma with IL-2 and IL-12 Using Gene Electrotransfer.International journal of molecular sciences · 2023Article
- Evaluating the Pharmacokinetics and Pharmacodynamics of Chemotherapeutics within a Spatial SILAC-Labeled Spheroid Model System.Analytical chemistry · 2023Article
- Protein post-translational modifications in the regulation of cancer hallmarks.Cancer gene therapy · 2023Review
- Vascular and Neuronal Network Formation Regulated by Growth Factors and Guidance Cues.Life (Basel, Switzerland) · 2023Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiangiogenesis was proposed as a novel target for the treatment of cancer 40 years ago. Since the original hypothesis put forward by Judah Folkman in 1971, factors that mediate angiogenesis, their cellular targets, many of the pathways they signal, and inhibitors of the cytokines and receptors have been identified. Vascular endothelial growth factor (VEGF) is the most prominent among the angiogenic cytokines and is believed to play a central role in the process of neovascularization, both in cancer as well as other inflammatory diseases. This article reviews the biology of VEGF and its receptors, the use of anti-VEGF approaches in clinical disease, the toxicity of these therapies, and the resistance mechanisms that have limited the activity of these agents when used as monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.